Incorporating Somatuline’s generic approval headwinds
07/01/22 -"Despite easing pandemic headwinds and recovering underlying markets, our EPS estimates reset lower as we take on board Somatuline’s sales erosion on account of the approval of its generic in the US. ..."
Pages
54
Language
English
Published on
07/01/22
You may also be interested by these reports :
20/08/26
Moderna’s late-stage skin cancer vaccine success nearly tripled its share price yesterday and opened a new realm within cancer treatment. Other ...
14/08/26
Since we last teased this name on 3 January 2025 — arguing there was little incremental upside left after a strong run and a post-merger valuation ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...